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ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
Lafeuille MH 1 , Bailey RA 2 , Laliberté F 1 , Senbetta M 2 , Vekeman F 3 , McKenzie RS 2 , Dea K 1 , Lefebvre P 1 1 Groupe d'analyse, Ltée, Montreal, QC, Canada, 2 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 3 Analysis Group, Inc., Washington, DC, USA OBJECTIVES: This study evaluated dosing trends and hemoglobin levels over time in patients with chronic kidney disease (CKD) not on dialysis receiving epoetin alfa (EPO) or darbepoetin alfa (DARB), 2 erythropoiesis-stimulating agents (ESAs). METHODS: An analysis of medical claims between July 2000 and March 2009 from the Ingenix IMPACT database was conducted. Patients ³18 years, newly initiated on ESAs, with ³1 claim for CKD were included. Patients diagnosed with cancer, receiving chemotherapy or dialysis, or receiving both agents were excluded. Average weekly ESA dose, weighted by the treatment duration, was calculated and reported by semester to evaluate trends over time. For the subset of patients with laboratory data, semi-annual mean of baseline and achieved hemoglobin levels were assessed over time. RESULTS: A total of 4,182 ESA-treated patients were identified (EPO 2684; DARB 1,498). Mean age was 64.2 and 63.2 in EPO and DARB groups, respectively, whereas proportion of women was 51% and 55%. The mean weekly dose was relatively stable for both ESAs over time (EPO: mean: 10,652 units; median: 10,623 units; 25th-75th percentiles: 9,872-11,609 units; DARB: mean: 41 mcg; median: 42 mcg; 25th-75th percentiles: 38-43 mcg); however, a slight decreasing trend was observed in more recent years (2006) (2007) (2008) . Analysis of laboratory results revealed a declining trend in mean baseline hemoglobin over time (10.5 g/dL in 2003S1 vs. 10 .1 g/dL in 2008S2) consistent with recent treatment guidelines. A decreasing trend was also observed in mean achieved hemoglobin during the treatment episode (11.9 g/dL in 2003S1 vs. 10.9 g/dL in 2008S2). Furthermore, the proportion of patients with achieved hemoglobin >12 g/dL decreased from 41% before April 2006 to 23% in April 2007, after the KDOQI guidelines changed. CONCLUSIONS: This analysis of data from CKD patients not on dialysis reported relatively stable ESA dosing trends and decreasing trend in hemoglobin levels during the study period. 
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POSTER SESSION II HEALTH CARE USE & POLICY STUDIES -Consumer Role in Health Care
PHP1 MORE EFFECTIVELY ENGAGING CONSUMERS IN COMPARATIVE EFFECTIVENESS RESEARCH
Seidenfeld JD 1 , Sonnad S 1 , Gruman J 2 1 Center for Medical Technology Policy, Baltimore, MD, USA, 2 Center for Advancing Health, Washington, DC, USA OBJECTIVES: Current efforts to influence health care using comparative effectiveness research (CER) often miss the opportunity to incorporate patient and consumer perspectives. The Center for Medical Technology Policy (CMTP) seeks to generate evidence for decision-makers and recognizes the importance of including patients and consumers as fellow decision-makers. This paper reports on the formation of and recommendations from a Patient and Consumer Advisory Committee (PCAC) for CMTP. METHODS: Following a literature review on consumer advocacy in health and interviews with experts regarding appropriate structure and training for effective patient and consumer engagement in CER, CMTP convened a workgroup of consumer and patient advocates to review practices and create a set of recommendations for strengthening the patient and consumer voice in CMTP's prioritization of technologies and development of guidelines for CER study designs. RESULTS: The workgroup's key recommendations for technology prioritization include 1) how and when to solicit input on technology topics from patient/consumer groups; 2) the role of patients/ consumers in setting priorities that reflect public values; 3) the information requirements of patients / consumers to serve as effective public representatives; and 4) the characteristics of patients/consumers that would contribute a broad perspective. For the development of study design guidelines, 1) gather patient/consumer information preferences via semi-structured interviews; 2) address patient/consumer identified outcomes; 3) consider having advocates who are also subject-matter experts review and comment on summaries from stakeholder meetings in addition to the public representatives who directly participate; and 4) consult with patient/consumer advocates about the suitability of disseminating project findings. CONCLUSIONS: As CER has expanded, a clear need has emerged for guidance on engaging public representatives in this area. There is a risk that the public's voice will be lost in the CER enterprise unless action is taken to champion and bring it to the forefront of the discussion.
